Group

Sdab 020

【小弟观察】盘点“流出”优优 第一季 哔哩哔哩

PS：该文章原创于年6月，之前在其他平台有发过，如果大家见过，那一定是出自本人手笔。今年可以说是“流出”元年了，业界频频爆出劲爆新闻，不停有优优的 Download sdabmp4 fast and secure Rapidgator Rapidgator: Fast, safe and secure file hosting News Upload file Web upload FTP Remote upload Premium Earn Support Login Download better_ fast and secure Rapidgator Rapidgator: Fast, safe and secure file hosting News Upload file Web upload FTP Remote upload Premium Earn

🔴 ここでビデオを見る ▼▼▼▼▼▼▼▼▼

In addition to being used as an injectable drug, the stable sdAbs can be also developed into aerosolized inhalations and disinfection products for the prevention of COVID CAS PubMed PubMed Central Google Scholar.Takeuchi, J.Structural elements of the ubiquitin-independent proteasome degron of ornithine decarboxylase.Park, E.A strategy for the generation of conditional mutations by protein destabilization.Natl Acad.USA 89 , — Ciechanover, A.Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting Nobel lecture.CAS PubMed Google Scholar.Dikic, I.Proteasomal and autophagic degradation systems.Zheng, N.Ubiquitin ligases: structure, function, and regulation.King, R.Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates.Cell 7 , — Roy, M.SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate.Robers, M.Quantitative, real-time measurements of intracellular target engagement using energy transfer.Methods Mol.Hjerpe, R.Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities.EMBO Rep.Emanuele, M.Global identification of modular cullin-RING ligase substrates.Feng, S.Improved split fluorescent proteins for endogenous protein labeling.Soucy, T.An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.Schlierf, A.Targeted inhibition of the COP9 signalosome for treatment of cancer.Anderson, D.Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis.Cancer Cell 28 , — Thank you for visiting nature.You are using a browser version with limited support for CSS.To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer.In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.Controlled perturbation of protein activity is essential to study protein function in cells and living organisms.Small molecules that hijack the cellular protein ubiquitination machinery to selectively degrade proteins of interest, so-called degraders, have recently emerged as alternatives to selective chemical inhibitors, both as therapeutic modalities and as powerful research tools.These systems offer unprecedented temporal and spatial control over protein function.Here, we review recent developments in this field, with a particular focus on the use of degraders as research tools to interrogate complex biological problems.This is a preview of subscription content, access via your institution.Nature Communications Open Access 06 October Anti-CD20 radioimmunotherapy is an effective approach for therapy of relapsed or refractory CD20 pos lymphomas, but faces limitations due to poor tumor penetration and undesirable pharmacokinetics of full antibodies.Camelid single-domain Ab fragments sdAb might circumvent some of the limitations of radiolabeled full antibodies.In this study, a set of hCDtargeting sdAbs was generated, and their capacity to bind hCD20 was evaluated in vitro and in vivo A lead sdAb, sdAb , was selected on the basis of its specific tumor targeting and significant lower kidney accumulation compared with other sdAbs.SdAb was then radiolabeled with 68 Ga and Lu for PET imaging and targeted therapy.The therapeutic potential of Lu-DTPA-sdAb was compared with that of Lu-DTPA-rituximab and unlabeled rituximab in mice bearing hCD20 pos tumors.Radiolabeled with 68 Ga, sdAb showed specific tumor uptake, with very low accumulation in nontarget organs, except kidneys.The tumor uptake of Lu-DTPA-sdAb after 1.Treatment of mice with Lu-DTPA-sdAb significantly prolonged median survival compared with control groups and was as effective as treatment with rituximab or its Lu-labeled variant.Taken together, sdAb displays promising features as a theranostic drug to treat CD20 pos lymphomas.Mol Cancer Ther; 16 12 ; e3